» Articles » PMID: 9550192

Glutamate Receptors in the Mammalian Central Nervous System

Overview
Journal Prog Neurobiol
Specialty Neurology
Date 1998 Apr 29
PMID 9550192
Citations 216
Authors
Affiliations
Soon will be listed here.
Abstract

Glutamate receptors (GluRs) mediate most of the excitatory neurotransmission in the mammalian central nervous system (CNS). In addition, they are involved in plastic changes in synaptic transmission as well as excitotoxic neuronal cell death that occurs in a variety of acute and chronic neurological disorders. The GluRs are divided into two distinct groups, ionotropic and metabotropic receptors. The ionotropic receptors (iGluRs) are further subdivided into three groups: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate and N-methyl-D-aspartate (NMDA) receptor channels. The metabotropic receptors (mGluRs) are coupled to GTP-binding proteins (G-proteins), and regulate the production of intracellular messengers. The application of molecular cloning technology has greatly advanced our understanding of the GluR system. To date, at least 14 cDNAs of subunit proteins constituting iGluRs and 8 cDNAs of proteins constituting mGluRs have been cloned in the mammalian CNS, and the molecular structure, distribution and developmental change in the CNS, functional and pharmacological properties of each receptor subunit have been elucidated. Furthermore, the obtained clones have provided valuable tools for conducting studies to clarify the physiological and pathophysiological significances of each subunit. For example, the generation of gene knockout mice has disclosed critical roles of some GluR subunits in brain functions. In this article, we review recent progress in the research for GluRs with special emphasis on the molecular diversity of the GluR system and its implications for physiology and pathology of the CNS.

Citing Articles

NMDA Receptors in Neurodevelopmental Disorders: Pathophysiology and Disease Models.

Tumdam R, Hussein Y, Garin-Shkolnik T, Stern S Int J Mol Sci. 2024; 25(22).

PMID: 39596430 PMC: 11594297. DOI: 10.3390/ijms252212366.


Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.

Yates J Subst Abuse Rehabil. 2024; 15:125-161.

PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.


Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.

Yates J Prog Neuropsychopharmacol Biol Psychiatry. 2024; 135:111107.

PMID: 39098647 PMC: 11409449. DOI: 10.1016/j.pnpbp.2024.111107.


Metabotropic glutamate receptor genetic variants and peripheral receptor expression affects trait scores of autistic probands.

Dutta N, Chatterjee M, Saha S, Sinha S, Mukhopadhyay K Sci Rep. 2024; 14(1):8558.

PMID: 38609494 PMC: 11014995. DOI: 10.1038/s41598-024-59290-2.


Association of glutamate receptor gene polymorphisms with attention-deficit hyperactivity disorder susceptibility: a systematic review and meta-analysis.

Zou D, Zeng Q, Liu P, Wei Y, Guo R, Zhu Y Front Genet. 2024; 15:1348387.

PMID: 38544802 PMC: 10965694. DOI: 10.3389/fgene.2024.1348387.